These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33131064)

  • 1. Efficacy of romiplostim in treatment of thrombocytopenia in children with Wiskott-Aldrich syndrome.
    Khoreva A; Abramova I; Deripapa E; Rodina Y; Roppelt A; Pershin D; Larin S; Voronin K; Maschan A; Novichkova G; Shcherbina A
    Br J Haematol; 2021 Jan; 192(2):366-374. PubMed ID: 33131064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Romiplostim for the management of perioperative thrombocytopenia.
    Al-Samkari H; Marshall AL; Goodarzi K; Kuter DJ
    Br J Haematol; 2018 Jul; 182(1):106-113. PubMed ID: 29767837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.
    Newland A; Godeau B; Priego V; Viallard JF; López Fernández MF; Orejudos A; Eisen M
    Br J Haematol; 2016 Jan; 172(2):262-73. PubMed ID: 26537623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.
    Tarantino MD; Bussel JB; Blanchette VS; Beam D; Roy J; Despotovic J; Raj A; Carpenter N; Mehta B; Eisen M
    Haematologica; 2019 Nov; 104(11):2283-2291. PubMed ID: 30846500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
    Tarantino MD; Bussel JB; Blanchette VS; Despotovic J; Bennett C; Raj A; Williams B; Beam D; Morales J; Rose MJ; Carpenter N; Nie K; Eisen M
    Lancet; 2016 Jul; 388(10039):45-54. PubMed ID: 27103127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.
    Marquínez-Alonso I; Escudero-Vilaplana V; Pernía S; Beléndez Bieler C; Fernández-Llamazares CM; Sanjurjo-Sáez M
    J Clin Pharm Ther; 2014 Aug; 39(4):376-82. PubMed ID: 24702274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.
    Fenaux P; Muus P; Kantarjian H; Lyons RM; Larson RA; Sekeres MA; Becker PS; Orejudos A; Franklin J
    Br J Haematol; 2017 Sep; 178(6):906-913. PubMed ID: 28616874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased requirement for platelet transfusions concurrent with enhanced bleeding during romiplostim treatment in a patient with thrombocytopenia due to bone marrow failure.
    Lotfi R; Moeller P; Schmid M; Schrezenmeier H
    Ann Hematol; 2011 Nov; 90(11):1357-9. PubMed ID: 21327404
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP).
    Gernsheimer TB; George JN; Aledort LM; Tarantino MD; Sunkara U; Matthew Guo D; Nichol JL
    J Thromb Haemost; 2010 Jun; 8(6):1372-82. PubMed ID: 20230419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
    Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
    Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis.
    Zhang J; Liang Y; Ai Y; Li X; Xie J; Li Y; Zheng W; He R
    Sci Rep; 2018 Jan; 8(1):576. PubMed ID: 29330464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experience.
    Pasquet M; Aladjidi N; Guiton C; Courcoux MF; Munzer M; Auvrignon A; Lutz P; Ducassou S; Leroy G; Munzer C; Leverger G;
    Br J Haematol; 2014 Jan; 164(2):266-71. PubMed ID: 24152194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia.
    Cines DB; Wasser J; Rodeghiero F; Chong BH; Steurer M; Provan D; Lyons R; Garcia-Chavez J; Carpenter N; Wang X; Eisen M
    Haematologica; 2017 Aug; 102(8):1342-1351. PubMed ID: 28411254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients.
    Hartranft ME; Clemmons AB; DeRemer DL; Kota V
    J Oncol Pharm Pract; 2017 Jan; 23(1):10-17. PubMed ID: 26471738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials.
    Tarantino MD; Despotovic J; Roy J; Grainger J; Cooper N; Beam D; Raj A; Maschan A; Kim J; Eisen M
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28630. PubMed ID: 32902132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia.
    Soff GA; Miao Y; Bendheim G; Batista J; Mones JV; Parameswaran R; Wilkins CR; Devlin SM; Abou-Alfa GK; Cercek A; Kemeny NE; Sarasohn DM; Mantha S
    J Clin Oncol; 2019 Nov; 37(31):2892-2898. PubMed ID: 31545663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.
    Khellaf M; Michel M; Quittet P; Viallard JF; Alexis M; Roudot-Thoraval F; Cheze S; Durand JM; Lefrère F; Galicier L; Lambotte O; Panelatti G; Slama B; Damaj G; Sebahoun G; Gyan E; Delbrel X; Dhedin N; Royer B; Schleinitz N; Rossi JF; Mahévas M; Languille L; Bierling P; Godeau B
    Blood; 2011 Oct; 118(16):4338-45. PubMed ID: 21832276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.
    Kantarjian HM; Fenaux P; Sekeres MA; Szer J; Platzbecker U; Kuendgen A; Gaidano G; Wiktor-Jedrzejczak W; Carpenter N; Mehta B; Franklin J; Giagounidis A
    Lancet Haematol; 2018 Mar; 5(3):e117-e126. PubMed ID: 29396092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Romiplostim in chemotherapy-induced thrombocytopenia: A review of the literature.
    Soff GA; Al-Samkari H; Leader A; Eisen M; Saad H
    Cancer Med; 2024 Aug; 13(15):e7429. PubMed ID: 39135303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial.
    Lee JW; Lee SE; Jung CW; Park S; Keta H; Park SK; Kim JA; Oh IH; Jang JH
    Lancet Haematol; 2019 Nov; 6(11):e562-e572. PubMed ID: 31474546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.